AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 147 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $131,034 | -7.9% | 5,294 | +5.4% | 0.00% | – |
| Q2 2023 | $142,225 | -38.7% | 5,022 | -50.3% | 0.00% | – |
| Q1 2023 | $231,956 | -99.5% | 10,098 | -99.4% | 0.00% | -100.0% |
| Q4 2022 | $46,060,026 | -14.6% | 1,640,314 | -14.0% | 0.01% | -16.7% |
| Q3 2022 | $53,919,000 | -17.2% | 1,906,554 | -35.1% | 0.01% | 0.0% |
| Q2 2022 | $65,088,000 | -53.6% | 2,935,842 | -39.1% | 0.01% | -45.5% |
| Q1 2022 | $140,266,000 | -21.5% | 4,818,492 | -11.3% | 0.01% | -15.4% |
| Q4 2021 | $178,626,000 | -43.5% | 5,434,314 | -20.7% | 0.01% | -48.0% |
| Q3 2021 | $316,074,000 | -29.0% | 6,848,818 | -15.3% | 0.02% | -28.6% |
| Q2 2021 | $445,400,000 | +9.5% | 8,082,010 | +2.6% | 0.04% | 0.0% |
| Q1 2021 | $406,867,000 | +116.4% | 7,878,905 | +81.6% | 0.04% | +105.9% |
| Q4 2020 | $187,994,000 | +40.3% | 4,338,667 | +13.3% | 0.02% | +21.4% |
| Q3 2020 | $134,011,000 | -55.4% | 3,828,886 | -31.8% | 0.01% | -57.6% |
| Q2 2020 | $300,361,000 | -5.9% | 5,616,327 | -37.6% | 0.03% | -25.0% |
| Q1 2020 | $319,163,000 | -24.3% | 8,995,579 | +1.9% | 0.04% | -6.4% |
| Q4 2019 | $421,559,000 | +47.6% | 8,828,462 | +0.2% | 0.05% | +38.2% |
| Q3 2019 | $285,539,000 | -35.0% | 8,812,932 | +0.1% | 0.03% | -33.3% |
| Q2 2019 | $439,278,000 | -25.6% | 8,806,700 | +0.5% | 0.05% | -28.2% |
| Q1 2019 | $590,728,000 | +46.8% | 8,759,313 | +0.4% | 0.07% | +29.1% |
| Q4 2018 | $402,393,000 | -40.0% | 8,726,801 | +0.3% | 0.06% | -26.7% |
| Q3 2018 | $670,858,000 | -7.8% | 8,698,886 | +0.7% | 0.08% | -10.7% |
| Q2 2018 | $727,818,000 | +3.5% | 8,640,843 | +0.5% | 0.08% | +1.2% |
| Q1 2018 | $703,227,000 | +68.3% | 8,599,011 | +17.6% | 0.08% | +69.4% |
| Q4 2017 | $417,898,000 | -13.7% | 7,309,743 | +0.7% | 0.05% | -16.9% |
| Q3 2017 | $484,517,000 | +30.3% | 7,258,679 | +0.4% | 0.06% | +28.3% |
| Q2 2017 | $371,846,000 | +0.6% | 7,227,331 | +14.1% | 0.05% | -2.1% |
| Q1 2017 | $369,774,000 | +40.7% | 6,331,747 | +0.5% | 0.05% | +34.3% |
| Q4 2016 | $262,849,000 | -19.9% | 6,298,816 | +1.4% | 0.04% | -20.5% |
| Q3 2016 | $328,069,000 | +37.7% | 6,211,072 | +9.3% | 0.04% | +33.3% |
| Q2 2016 | $238,163,000 | +3.4% | 5,684,768 | +0.2% | 0.03% | +3.1% |
| Q1 2016 | $230,368,000 | -37.2% | 5,674,084 | +0.5% | 0.03% | -34.7% |
| Q4 2015 | $366,544,000 | -7.5% | 5,646,095 | +0.5% | 0.05% | -12.5% |
| Q3 2015 | $396,472,000 | -36.2% | 5,616,553 | +0.4% | 0.06% | -30.0% |
| Q2 2015 | $621,798,000 | +18.1% | 5,594,725 | +0.2% | 0.08% | +19.4% |
| Q1 2015 | $526,455,000 | -14.5% | 5,582,768 | +1.6% | 0.07% | -16.2% |
| Q4 2014 | $615,587,000 | +91.1% | 5,494,348 | +4.6% | 0.08% | +81.8% |
| Q3 2014 | $322,116,000 | +38.1% | 5,250,459 | +3.1% | 0.04% | +41.9% |
| Q2 2014 | $233,299,000 | +63.7% | 5,091,646 | +39.9% | 0.03% | +55.0% |
| Q1 2014 | $142,533,000 | +166.7% | 3,640,679 | +63.1% | 0.02% | +150.0% |
| Q4 2013 | $53,446,000 | -14.3% | 2,231,565 | 0.0% | 0.01% | -20.0% |
| Q3 2013 | $62,395,000 | – | 2,231,565 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |